Tempus AI (NASDAQ:TEM) Given New $60.00 Price Target at Bank of America

Tempus AI (NASDAQ:TEM) had its price target lifted by analysts at Bank of America from $54.00 to $60.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Bank of America‘s price objective would indicate a potential upside of 6.80% from the stock’s current price.

Other equities research analysts have also issued reports about the stock. TD Cowen reiterated a “buy” rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. William Blair reaffirmed a “market perform” rating on shares of Tempus AI in a research report on Tuesday, February 25th. JPMorgan Chase & Co. cut Tempus AI from an “overweight” rating to a “neutral” rating and increased their price target for the company from $50.00 to $55.00 in a research report on Tuesday, February 25th. Guggenheim restated a “buy” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Finally, Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and upped their price objective for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $61.09.

Tempus AI Trading Up 1.6 %

NASDAQ:TEM opened at $56.18 on Monday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI has a twelve month low of $22.89 and a twelve month high of $91.45. The business has a 50 day moving average price of $52.70 and a two-hundred day moving average price of $52.52.

Insider Buying and Selling

In other Tempus AI news, CAO Ryan M. Bartolucci sold 13,770 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $60.00, for a total value of $826,200.00. Following the completion of the sale, the chief accounting officer now owns 57,237 shares of the company’s stock, valued at $3,434,220. The trade was a 19.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Eric P. Lefkofsky sold 187,655 shares of the stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total value of $7,044,568.70. Following the sale, the chief executive officer now directly owns 9,557,283 shares in the company, valued at $358,780,403.82. This represents a 1.93 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,823,701 shares of company stock valued at $320,906,059.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TEM. Operose Advisors LLC bought a new position in shares of Tempus AI in the 4th quarter valued at $25,000. First Horizon Advisors Inc. bought a new position in Tempus AI in the third quarter valued at about $30,000. Farther Finance Advisors LLC acquired a new position in Tempus AI during the fourth quarter worth about $34,000. Prestige Wealth Management Group LLC lifted its holdings in shares of Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after acquiring an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC acquired a new stake in shares of Tempus AI in the 4th quarter valued at approximately $49,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.